KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Net Margin (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Net Margin for 17 consecutive years, with 8.69% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 807.0% to 8.69% in Q4 2025 year-over-year; TTM through Dec 2025 was 14.64%, a 3337.0% increase, with the full-year FY2025 number at 14.64%, up 3314.0% from a year prior.
  • Net Margin was 8.69% for Q4 2025 at Bristol Myers Squibb, down from 17.96% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 21.98% in Q1 2025 to a low of 100.36% in Q1 2024.
  • A 5-year average of 8.38% and a median of 13.85% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: plummeted -12036bps in 2024, then surged 12234bps in 2025.
  • Bristol Myers Squibb's Net Margin stood at 19.79% in 2021, then decreased by -10bps to 17.75% in 2022, then fell by -16bps to 14.87% in 2023, then tumbled by -96bps to 0.62% in 2024, then skyrocketed by 1311bps to 8.69% in 2025.
  • Per Business Quant, the three most recent readings for BMY's Net Margin are 8.69% (Q4 2025), 17.96% (Q3 2025), and 10.7% (Q2 2025).